FORMULARY
THE JOURNAL FOR MANAGED CARE AND HOSPITAL DECISION MAKERS

SUBJECT INDEX TO VOLUME 30

A

abciximab
  ReoPro, update on, 131 (Mar)
acarbose
  Precose, update on, 639 (Nov)
ACE inhibitors
  routine prescribing of, for CHF (abstr), 474 (Aug)
acetaminophen
  acute low back pain, for Tx of, 70 (Feb)
acyclovir
  low-dose, for prophylaxis against herpes simplex virus, 720 (Nov)
acute lymphocytic leukemia
  asparaginase vs pegaspargase for Tx of, in adults, 388 (Jul)
adenosine injection
  Adenoscan, update on, 422 (Aug)
adverse drug reactions
  computers, use of, for decreasing, 568 (Oct)
  reporting of, 226 (Apr); 454, 471 (Aug); 697 (Nov)
AG 1343
  HIV infection, for Tx of, 722 (Nov)
Agency for Health Care Policy and Research
  quality care guidelines, publishes, 567 (Oct)
alendronate sodium
  Fosamax, update on, 746 (Dec)
  osteoporosis, for Tx of, 433 (Aug)
alteplase, recombinant
  Activase, update on, 304 (Jun)
alprostadil for injection
  Caverject Sterile Powder, update on, 488 (Sept)
amikacin sulfate
  evaluating use of, 114 (Feb)
amiodarone
  Cordarone IV, update on, 636 (Nov)
  focus on, 509 (Sept)
amlodipine
  safety of, in patients with class-III or -IV heart failure, 253 (May)
amlodipine besylate/benazepril HCl
  Lotrel, update on, 556 (Oct)
amoxicillin/clavulanate potassium
  acute otitis media, for Tx of, 721 (Nov)
amphetamine sulfate mixture
  Adderall/Obetrol, update on, 68 (Feb)
amphotericin B lipid complex
  conventional form, vs, for Tx of invasive candidiasis, 722 (Nov)
androgen deprivation therapy
  prostate cancer, for Tx of, 567 (Oct)
antibiotics
  disease-based-outcome approach to use of, 139 (Mar)
  empiric use of, evaluated, 252 (May)
  newer, physician prescribing of, 292 (May)
  pharmaceutical restriction program for controlling use of, 711 (Nov)
  restriction program for, 722 (Nov)
  therapeutic interchange program for, 92 (Feb)
  true costs of using, 310 (Jun)
anticoagulants
  focus on, 657 (Nov)
anticoagulation
  benefits outweigh costs of (abstr), 410 (Jul)
  venous thromboembolism, for extended Tx of (abstr), 621 (Oct)
antidepressants
  pharmacologic rationale for Tx and product selection of (Suppl), S-10 (Sept)
antiemetic protection
  combination of granisetron and dexamethasone, better than either drug alone for (abstr), 821 (Dec)
  granisetron financially attractive vs ondansetron, 72 (Feb)
antimicrobials
  switching from IV to oral, 343 (Jun)
antithrombin III
  developing guidelines for use of, 520 (Sept)
arrhythmia
  acute, amiodarone for Tx of, 509 (Sept)
  dofetilide for Tx of, 23 (Jan)
arthritis, rheumatoid
  cyclosporine or prednisolone as adjunctive therapy for (abstr), 723 (Nov)
  misoprostol prevents diclofenec-induced gastric ulcers in (abstr), 830 (Dec)
asparaginase
  pegaspargase, vs, for Tx of acute lymphocytic leukemia in adults, 388 (Jul)
atorvastatin
  update on, 248 (May)
atovaquone
  Mepron Suspension, update on, 427 (Aug)
azelaic acid cream
  Azelex 20%, update on, 745 (Dec)
azithromycin
  community-acquired pneumonia, as adjuvant therapy for, 817 (Dec)

B

baclofen injection, USP
  Lioresal Intrathecal, update on, 304 (Jun)
benign prostatic hyperplasia
  terazosin vs finasteride for Tx of, 650 (Nov)
beta blockers
  silent ischemia, for Tx of (abstr), 176 (Mar)
  underuse of, after MI, 370 (Jul)
bicalutamide
  Casodex, update on , 745 (Dec)
  LHRH analogue, plus, for Tx of prostate cancer, 377 (Jul)
biotech products
  developing guidelines for use of, 520 (Sept)
  issues surrounding, 19 (Jan)
bisoprolol
  HTN, alone or with hydrochlorothiazide for Tx of (abstr), 56 (Jan)

C

calcium channel blockers
  use of, in patients with HTN, 251 (May)
cancer
  breast:
    cyclophosphamide as adjuvant Tx for, 500 (Sept)
  lung:
    chemotherapy is clinically and economically justified (abstr), 822 (Dec)
  ovarian:
    paclitaxel for Tx of, 434 (Aug)
  prostate:
    androgen deprivation therapy for Tx of, 567 (Oct)
    bicalutamide/LHRH analogue for Tx of, 377 (Jul)
    hormone therapy is appropriate alternative for low-grade, 760 (Dec)
candidiasis, invasive
  amphotericin B lipid complex vs standard form for Tx of, 722 (Nov)
carbachol
  Carbastat, update on, 422 (Aug)
cardiovascular disease
  warfarin for Tx of, 657 (Nov)
carotid artery atherosclerosis
  pravastatin sodium for Tx of, 79 (Feb)
carvedilol
  Coreg, update on, 745 (Dec)
cefpodoxime proxetil, flavored granules for suspension
  Vantin Oral Suspension, update on, 495 (Sept)
ceftazidime
  piperacillin/tazobactam, vs, for Tx of hospital-acquired lower respiratory tract infections, 563 (Oct)
ceftibuten
  focus on, 85 (Feb)
ceftriaxone
  DUE of, in pediatric population, 615 (Oct)
chest pain
  technetium (Tc)-99m sestamibi for assessment of, 74 (Feb)
chickenpox vaccine
  Varivax, update on, 305 (Jun)
Chlamydia trachomatis cervicitis
  doxycycline as cost-effective Tx for (abstr), 291 (May)
cholesterol
  colestipol and lovastatin for lowering LDL (abstr), 236 (Apr)
  HDL, as baseline for response to lipid-lowering therapy (abstr), 291 (May)
  lowering, cost-effectiveness of, in patients with CAD, 257 (May)
  simvastatin for lowering, in patients with CHD, 254 (May)
  statin therapy for lowering, in patients with CAD, 253 (May)
cholestyramine tablets
  Questran Tablets, update on, 12 (Jan)
cidofovir IV
  cytomegalovirus retinitis, for Tx of, 721 (Nov)
  Vistide, update on, 640 (Nov)
ciprofloxacin HCl
  Cipro, update on, 189 (Apr)
  three-day regimen of, for Tx of uncomplicated UTI (abstr), 474 (Aug)
cisapride, liquid suspension
  Propulsid, update on, 755 (Dec)
cisapride tablets
  Propulsid, update on, 131 (Mar)
clarithromycin
  omeprazole, and, for Tx of duodenal ulcers associated with *H pylori* infection, 431 (Aug)
clobetasol propionate
  Temovate Emollient Cream, 0.05%/Temovate Gel, 0.05%, update on, 70 (Feb)
codeine phosphate 10 mg/guaifenesin 300 mg
  Brontex, update on, 10 (Jan)
cognitive services
  developing program for, for pharmacists, 319 (Jun)
  issues surrounding, 320 (Jun)
colestipol/lovastatin
  LDL cholesterol, for lowering (abstr), 236 (Apr)
compliance, patient
  improving, 319 (Jun); 596 (Oct)
computer(s)
  ADRs, for use in decreasing, 568 (Oct)
  drug distribution system, for use in, 106 (Feb)
  pain management, use of in, 70 (Feb)
  software, adapting, for ADR reporting, 697 (Nov)
  telephone program, and, for urging patient compliance, 496 (Sept)
congestive heart failure

FORMULARY
THE JOURNAL FOR MANAGED CARE AND HOSPITAL DECISION MAKERS

SUBJECT INDEX TO VOLUME 30

A

abciximab
  ReoPro, update on, 131 (Mar)
acarbose
  Precose, update on, 639 (Nov)
ACE inhibitors
  routine prescribing of, for CHF (abstr), 474 (Aug)
acetaminophen
  acute low back pain, for Tx of, 70 (Feb)
acyclovir
  low-dose, for prophylaxis against herpes simplex virus, 720 (Nov)
acute lymphocytic leukemia
  asparaginase vs pegaspargase for Tx of, in adults, 388 (Jul)
adenosine injection
  Adenoscan, update on, 422 (Aug)
adverse drug reactions
  computers, use of, for decreasing, 568 (Oct)
  reporting of, 226 (Apr); 454, 471 (Aug); 697 (Nov)
AG 1343
  HIV infection, for Tx of, 722 (Nov)
Agency for Health Care Policy and Research
  quality care guidelines, publishes, 567 (Oct)
alendronate sodium
  Fosamax, update on, 746 (Dec)
  osteoporosis, for Tx of, 433 (Aug)
alteplase, recombinant
  Activase, update on, 304 (Jun)
alprostadil for injection
  Caverject Sterile Powder, update on, 488 (Sept)
amikacin sulfate
  evaluating use of, 114 (Feb)
amiodarone
  Cordarone IV, update on, 636 (Nov)
  focus on, 509 (Sept)
amlodipine
  safety of, in patients with class-III or -IV heart failure, 253 (May)
amlodipine besylate/benazepril HCl
  Lotrel, update on, 556 (Oct)
amoxicillin/clavulanate potassium
  acute otitis media, for Tx of, 721 (Nov)
amphetamine sulfate mixture
  Adderall/Obetrol, update on, 68 (Feb)
amphotericin B lipid complex
  conventional form, vs, for Tx of invasive candidiasis, 722 (Nov)
androgen deprivation therapy
  prostate cancer, for Tx of, 567 (Oct)
antibiotics
  disease-based-outcome approach to use of, 139 (Mar)
  empiric use of, evaluated, 252 (May)
  newer, physician prescribing of, 292 (May)
  pharmaceutical restriction program for controlling use of, 711 (Nov)
  restriction program for, 722 (Nov)
  therapeutic interchange program for, 92 (Feb)
  true costs of using, 310 (Jun)
anticoagulants
  focus on, 657 (Nov)
anticoagulation
  benefits outweigh costs of (abstr), 410 (Jul)
  venous thromboembolism, for extended Tx of (abstr), 621 (Oct)
antidepressants
  pharmacologic rationale for Tx and product selection of (Suppl), S-10 (Sept)
antiemetic protection
  combination of granisetron and dexamethasone, better than either drug alone for (abstr), 821 (Dec)
  granisetron financially attractive vs ondansetron, 72 (Feb)
antimicrobials
  switching from IV to oral, 343 (Jun)
antithrombin III
  developing guidelines for use of, 520 (Sept)
arrhythmia
  acute, amiodarone for Tx of, 509 (Sept)
  dofetilide for Tx of, 23 (Jan)
arthritis, rheumatoid
  cyclosporine or prednisolone as adjunctive therapy for (abstr), 723 (Nov)
  misoprostol prevents diclofenec-induced gastric ulcers in (abstr), 830 (Dec)
asparaginase
  pegaspargase, vs, for Tx of acute lymphocytic leukemia in adults, 388 (Jul)
atorvastatin
  update on, 248 (May)
atovaquone
  Mepron Suspension, update on, 427 (Aug)
azelaic acid cream
  Azelex 20%, update on, 745 (Dec)
azithromycin
  community-acquired pneumonia, as adjuvant therapy for, 817 (Dec)

B

baclofen injection, USP
  Lioresal Intrathecal, update on, 304 (Jun)
benign prostatic hyperplasia
  terazosin vs finasteride for Tx of, 650 (Nov)
beta blockers
  silent ischemia, for Tx of (abstr), 176 (Mar)
  underuse of, after MI, 370 (Jul)
bicalutamide
  Casodex, update on , 745 (Dec)
  LHRH analogue, plus, for Tx of prostate cancer, 377 (Jul)
biotech products
  developing guidelines for use of, 520 (Sept)
  issues surrounding, 19 (Jan)
bisoprolol
  HTN, alone or with hydrochlorothiazide for Tx of (abstr), 56 (Jan)

C

calcium channel blockers
  use of, in patients with HTN, 251 (May)
cancer
  breast:
    cyclophosphamide as adjuvant Tx for, 500 (Sept)
  lung:
    chemotherapy is clinically and economically justified (abstr), 822 (Dec)
  ovarian:
    paclitaxel for Tx of, 434 (Aug)
  prostate:
    androgen deprivation therapy for Tx of, 567 (Oct)
    bicalutamide/LHRH analogue for Tx of, 377 (Jul)
    hormone therapy is appropriate alternative for low-grade, 760 (Dec)
candidiasis, invasive
  amphotericin B lipid complex vs standard form for Tx of, 722 (Nov)
carbachol
  Carbastat, update on, 422 (Aug)
cardiovascular disease
  warfarin for Tx of, 657 (Nov)
carotid artery atherosclerosis
  pravastatin sodium for Tx of, 79 (Feb)
carvedilol
  Coreg, update on, 745 (Dec)
cefpodoxime proxetil, flavored granules for suspension
  Vantin Oral Suspension, update on, 495 (Sept)
ceftazidime
  piperacillin/tazobactam, vs, for Tx of hospital-acquired lower respiratory tract infections, 563 (Oct)
ceftibuten
  focus on, 85 (Feb)
ceftriaxone
  DUE of, in pediatric population, 615 (Oct)
chest pain
  technetium (Tc)-99m sestamibi for assessment of, 74 (Feb)
chickenpox vaccine
  Varivax, update on, 305 (Jun)
Chlamydia trachomatis cervicitis
  doxycycline as cost-effective Tx for (abstr), 291 (May)
cholesterol
  colestipol and lovastatin for lowering LDL (abstr), 236 (Apr)
  HDL, as baseline for response to lipid-lowering therapy (abstr), 291 (May)
  lowering, cost-effectiveness of, in patients with CAD, 257 (May)
  simvastatin for lowering, in patients with CHD, 254 (May)
  statin therapy for lowering, in patients with CAD, 253 (May)
cholestyramine tablets
  Questran Tablets, update on, 12 (Jan)
cidofovir IV
  cytomegalovirus retinitis, for Tx of, 721 (Nov)
  Vistide, update on, 640 (Nov)
ciprofloxacin HCl
  Cipro, update on, 189 (Apr)
  three-day regimen of, for Tx of uncomplicated UTI (abstr), 474 (Aug)
cisapride, liquid suspension
  Propulsid, update on, 755 (Dec)
cisapride tablets
  Propulsid, update on, 131 (Mar)
clarithromycin
  omeprazole, and, for Tx of duodenal ulcers associated with *H pylori* infection, 431 (Aug)
clobetasol propionate
  Temovate Emollient Cream, 0.05%/Temovate Gel, 0.05%, update on, 70 (Feb)
codeine phosphate 10 mg/guaifenesin 300 mg
  Brontex, update on, 10 (Jan)
cognitive services
  developing program for, for pharmacists, 319 (Jun)
  issues surrounding, 320 (Jun)
colestipol/lovastatin
  LDL cholesterol, for lowering (abstr), 236 (Apr)
compliance, patient
  improving, 319 (Jun); 596 (Oct)
computer(s)
  ADRs, for use in decreasing, 568 (Oct)
  drug distribution system, for use in, 106 (Feb)
  pain management, use of in, 70 (Feb)
  software, adapting, for ADR reporting, 697 (Nov)
  telephone program, and, for urging patient compliance, 496 (Sept)
congestive heart failure

ACE inhibitors, routine prescribing of, for Tx of (abstr), 474 (Aug)
closing formulary reduced costs of, 762 (Dec)
digoxin continued as therapy for (abstr), 621 (Oct)
Contract with America (GOP)
health issues and, 118 (Feb)
coronary heart disease
HMG-CoA reductase inhibitors for Tx of, 74 (Feb)
critical care pathways
development of, 504 (Sept)
Crohn's disease
methotrexate for Tx of (abstr), 410 (Jul)
cromolyn sodium ophthalmic solution USP, 4%
Crolom, update on, 248 (May)
cyclophosphamide
breast cancer, as adjuvant Tx for, 500 (Sept)
cyclosporine
rheumatoid arthritis, as adjunctive therapy for, 723 (Nov)
cyclosporine capsules and oral solution for microemulsion
Neoral Soft Gelatin Capsules and Neoral Oral Solution, update on, 557 (Oct)
cysteamine bitartrate
Cystagon, update on, 68 (Feb)
cystic fibrosis
dornase alfa for Tx of, 15 (Jan)
cytomegalovirus retinitis
cidofovir for Tx of, 721 (Nov)

D

dalteparin sodium injection
Fragmin, update on, 129 (Mar)
depression, major
issues in diagnosis of (Suppl), S-3 (Sept)
nefazodone for Tx of, 205 (Apr)
desmopressin acetate
DDAVP, update on, 556 (Oct)
dexrazoxone for injection
Zinecard, update on, 495 (Sept)
diabetes mellitus, noninsulin-dependent
glipizide to glyburide conversion in patients with, 405 (Jul)
metformin for Tx of, 383 (Jul)
diazepam injectable
Dizac, update on, 490 (Sept)
digoxin
congestive heart failure, as continued therapy for (abstr), 621 (Oct)
diltiazem HCl, controlled-release
Dilacor XR, update on, 248 (May)
dinoprostone vaginal insert
Cervidil, update on, 304 (Jun)
dirithromycin tablets
Dynabac, update on, 639 (Nov)
focus on, 769 (Dec)
disease-state management
developing program for, 17 (Jan); 326 (Jun)
managed care organizations and, 431 (Aug)
pharmaceutical industry's role in developing programs for (FormuFax), 409 (Jul)
popularity of, in managed care organizations, 251 (May)
role and benefits of, 502 (Sept)
divalproex sodium
Depakote Tablets, update on, 423 (Aug)
dofetilide
focus on, 23 (Jan)
dornase alfa
wider use of, urged in patients with cystic fibrosis, 15 (Jan)
dorzolamide ophthalmic solution
Trusopt, update on, 132 (Mar)
doxazosin mesylate
Cardura, update on, 189 (Apr)
evaluating use of, 233 (Apr)
doxycycline
cost-effectiveness, in Tx of *C trachomatis* cervicitis (abstr), 291 (May)
drug approvals
FDA and process for, 58 (Jan); 412 (Jul)
new in 1994, 81 (Feb)
shortened process for, and formulary decision making (FormuFax), 290 (May); (FormuFax) 409 (Jul)
drug blood levels
monitoring, starting program for, 284 (May)
drug costs
economic analysis and, 381 (Jul)
examining, 379 (Jul)
legislation and (FormuFax), 55 (Jan)
physicians' perceptions and knowledge of, 268 (May)
strategies for containing, 606 (Oct)
drug discounts
legislation regulating, 354 (Jun); (letter) 543 (Sept)
drug distribution system
use of computers in, 106 (Feb)
US, future of, 18 (Jan)
drug resistance
antibiotic, hospital formularies contribute to, 721 (Nov)
pneumococcal strains and (abstr), 56 (Jan)
vancomycin, controlling, 719 (Nov), 756 (Dec)
drug selection
pharmacodynamic principles for, 140 (Mar)
drug use evaluation
evaluating criteria for, 280 (May)
drug use labeling
pediatric, FDA guidelines for, 133 (Mar)
duodenal ulcer
H pylori-associated, Tx of, 431 (Aug)
lansoprazole for Tx of, 437 (Aug)

E

elderly
enalapril or lisinopril for Tx of HTN in (abstr), 292 (May)
felodipine for Tx of ischemia in (abstr), 176 (Mar)
HTN, Tx of, in, 148 (Mar)
misoprostol for prevention of GI problems in, with rheumatoid arthritis, 561 (Oct)
nimodipine facilitates learning of, 134 (Mar)
enalapril
HTN, for Tx of, in elderly (abstr), 292 (May)
enoxaparin sodium
knee replacement surgery, for use after, 657 (Nov)
Lovenox, update on, 305 (Jun)
enteral nutrition support
evaluating service for, 714 (Nov)
epilepsy
tiagabine HCl for Tx of intractable, 133 (Mar)
epoprostenol sodium
Flolan for injection, update on, 746 (Dec)
ergonovine maleate injection
Ergotrate, update on, 368 (Jul)
erosive esophagitis
lansoprazole for Tx of, 437 (Aug)
estrogen (estradiol) transdermal patch
Climara, update on, 367 (Jul)
estrogen/progestin
Prempro/Premphase, update on, 250 (May)
estrogen replacement therapy
benefits vs risks of, 500 (Sept)
cardiac benefits of, 78 (Feb)

F

famciclovir
focus on, 587 (Oct)
FDA
mandatory patient information in packages inserts, proposes, 622 (Oct)
politics and reform of, 476 (Aug)
reform of, as issue in Congress, 294 (May)
regulation of scientific information exchange, and (FormuFax), 619 (Oct)
role of, in healthcare reform, 178 (Mar)
felodipine
elderly, for Tx of ischemia in (abstr), 176 (Mar)
Plendil, update on, 305 (Jun); 639 (Nov)
filgrastim
evaluating costs and benefits of, 394 (Jul)
Neupogen, update on, 130 (Mar)
finasteride
Proscar, update on, 368 (Jul)
terazosin, vs, for Tx of BPH, 650 (Nov)
fleroxacin
focus on, 261 (May)
fluoroquinolones
tendon rupture, and, 189 (Apr)
flumazenil 0.1 mg/ml
Romazicon, update on, 194 (Apr)
flunisolide, 0.025% nasal solution
Nasarel, update on, 755 (Dec)
Fluticasone propionate nasal spray
Flonase, update on, 11 (Jan)
fluvoxamine maleate tablets
Luvox, update on, 69 (Feb)
formularies, closed
increasing among HMOs, 650 (Nov)
formulary
closing of, reduced CHF costs, 762 (Dec)
design and management of, 586 (Oct)
developing and implementing for a state's mental health and mental retardation facilities, 808 (Dec)
physician/patient compliance with, tips for improving, 571 (Oct)
strategies for management of, 572 (Oct)
formulary decision making
current strategies and new factors for, 462 (Aug)
pharmacoeconomics and, 42 (Jan)
foscarnet
dosing guidelines for, 349 (Jun)
foscarnet sodium
Foscavir Injection, update on, 490 (Sept)
fosinopril sodium
Monopril, update on, 557 (Oct)

G

ganciclovir, oral
Cytovene, update on, 128 (Mar)
gastroesophageal reflux disease
omeprazole, more costly yet more cost effective in, 760 (Dec)
omeprazole, role of, in Tx of, 216 (Apr)
gemcitabine HCl
Gemzar, update on, 193 (Apr)
generic substitution
managed care setting, in (FormuFax), 291 (May)
pharmacists' attitudes toward, 71 (Feb)
glipizide
newer form of, superior (abstr), 236 (Apr)
gonadotropin-releasing hormone
use of, before uterine leiomyoma surgery, 532 (Sept)
granisetron
Kytril Tablets, update on, 250 (May)
ondansetron, vs, as financially attractive agent, 72 (Feb)

H

haloperidol for IM injection
Haldol, update on, 11 (Jan)
healthcare reform
FDA's role in, 178 (Mar)

marketplace should dictate, 172 (Mar)
heart failure
amlodipine, safety of, in patients with class-III or -IV, 253 (May)
Helicobacter pylori infections
role and Tx of, in patients with peptic ulcers, 28 (Jan)
strategies for the Tx of, 682 (Nov)
hepatitis A vaccine
Havrix, update on, 249 (May); 423 (Aug)
hepatitis B
advantages of interferon alpha 2b in Tx of (abstr), 724 (Nov)
interferon alpha 2b cost-effective therapy for, 370 (Jul)
hepatitis B vaccine
Engerix-B, update on, 189 (Apr)
hepatitis, non-A/non-B
interferon alfa 2b for Tx of chronic (abstr), 544 (Sept)
herpes simplex virus
famciclovir for Tx of genital, 587 (Oct)
low-dose acyclovir for prophylaxis against, 720 (Nov)
HIV-associated infections
dosing guidelines for two drugs used in Tx of, 349 (Jun)
HIV infection
AG 1343 for Tx of, 722 (Nov)
saquinavir, slower rate of resistance compared with other proteinase inhibitors, 759 (Dec)
zidovudine/zalcitabine/saquinavir for Tx of, 720 (Nov)
HMG-CoA reductase inhibitors
coronary heart disease, for Tx of, 74 (Feb)
HMOs
profits of and enrollment in, 134 (Mar)
Hodgkin's disease
peripheral blood progenitor cell transplantation plus granulocyte colony-stimulating factor for Tx of, 652 (Nov)
hydromorphone HCl
Dilaudid-HP, update on, 423 (Aug)
hypercholesterolemia
lovastatin vs niacin for Tx of, 21 (Jan)
hypersecretory conditions
lansoprazole for Tx of, 437 (Aug)
hypertension
bisoprolol alone or with hydrochlorothiazide for Tx of (abstr), 56 (Jan)
calcium channel blockers, use of, in patients with, 251 (May)
elderly, Tx of, in, 148 (Mar)
enalapril or lisinopril for Tx of (abstr), 292 (May)
older drugs for Tx of, used less often, 313 (Jun)
single drug, sequential therapy works as effectively as add-on therapy, 756 (Dec)

I

imipenem
seizure incidence associated with, 172 (Mar)
immunomodulator therapy
inflammatory bowel disease, for Tx of severe, 784 (Dec)
incentive programs
evaluating, 655 (Nov)
pharmacists, and, 134 (Mar)
infections
intra-abdominal:
meropenem for Tx of, 374 (Jul)
lower respiratory:
piperacillin/tazobactam vs ceftazidime for Tx of hospital-acquired, 563 (Oct)
piperacillin/tazobactam vs ticarcillin/clavulanate for Tx of, 719 (Nov)
respiratory, urogenital:
ceftibuten for Tx of, 85 (Feb)
skin and soft-tissue:
meropenem for Tx of (abstr), 724 (Nov)
infectious diseases
fleroxacin for Tx of various, 261 (May)
inflammatory bowel disease
immunomodulator therapy for, 784 (Dec)
insulin, human
Novolin, update on, 639 (Nov)
Velosulin BR, update on, 755 (Dec)
integrated delivery systems
role and benefits of, 502 (Sept)
interferon alfa 2b
chronic hepatitis, for Tx of (abstr), 544 (Sept); (abstr), 724 (Nov)
interferon alpha 2b
hepatitis B, cost-effective therapy for, 370 (Jul)
interferon beta-1A (recombinant)
multiple sclerosis, for Tx of, 655 (Nov)
interferon beta-1b
Betaseron, update on, 10 (Jan)
iopromide
Ultravist Injection, update on, 428 (Aug)
ipratropium bromide, nasal spray
Atrovent, update on, 740 (Dec)
ischemia
silent, beta blockers for Tx of (abstr), 176 (Mar)
ischemic stroke
IV t-PA for Tx of, 198 (Apr)
itraconazole
Sporanox, update on, 755 (Dec)

J

JCAHO
Indicator Measurement System, adds new indicators to, 374 (Jul)

K

ketoprofen, extended release
Oruvail Extended-Release Capsules, update on, 193 (Apr)
ketorolac tromethamine
Toradol, update on, 194 (Apr)
knee replacement surgery
enoxaparin for use after, 675 (Nov)

L

lamotrigine
Lamictal, update on, 129 (Mar)
lansoprazole
focus on, 437 (Aug)
Prevacid Delayed-Release Capsules, update on, 427 (Aug)
leuprolide acetate for depot suspension
Lupron Depot 3.75 mg, update on, 368 (Jul)
leutenizing hormone-releasing hormone analogue
bicalutamide, and, for Tx of prostate cancer, 377 (Jul)
levothyroxine sodium
Levoxyl/Levoxine, update on, 69 (Feb)
lisinopril
HTN, for Tx of, in elderly (abstr), 292 (May)
loratadine 5 mg/extended-release pseudoephedrine sulfate 120 mg
Claritan, update on, 745 (Dec)
Claritin-D, update on, 68 (Feb)
losartan potassium
Cozaar, update on, 368 (Jul)
losartan potassium/hydrocholorothiazide tablets
Hyzaar, update on, 423 (Aug)
lovastatin
colestipol, and, for lowering LDL cholesterol (abstr), 236 (Apr)
Mevacor, update on, 130 (Mar)
niacin, vs, for Tx of hypercholesterolemia, 21 (Jan)
low back pain, acute
acetaminophen, NSAIDs for primary Tx of, 70 (Feb)
lymphoma
peripheral blood progenitor cell transplantation plus granulocyte colony-stimulating factor for Tx of, 652 (Nov)

M

malignant glioma, implantable polymer drug delivery system
Gliadel, update on, 746 (Dec)
mammalian cell-derived recombinant human growth hormone
Serostim, update on, 194 (Apr)
managed care marketplace
FDA considers effects of, on drug promotional practices, 840 (Dec)
managed care organizations
cooperation among (FormuFax), 620 (Oct)
disease management programs, and, 431 (Aug)
financial risk sharing and, 314 (Jun)
generic substitutions and (FormuFax), 291 (May)
MD-patient relationship, and, 201 (Apr)
P & T Committees, adapting to, 138 (Mar)
popularity of disease-state management in, 251 (May)
review of, for accreditation, 503 (Sept)
managed care programs
calculating cost savings of, 380 (Jul)
Medicaid
California, formulary review in, 432 (Aug)
cost saving opportunities in, 758 (Dec)
drug management and, 577 (Oct)
Medicare, and, proposed reforms of, 546 (Sept)
prior authorization system for, 499 (Sept)
reform of, as issue in Congress, 294 (May)
Medicare
key issues in reform of, 730 (Nov)
medication errors
reporting of (FormuFax), 53 (Jan)
meropenem
intra-abdominal infections, for Tx of, 374 (Jul)
skin and soft-tissue infections, for Tx of (abstr), 724 (Nov)
metformin HCl
focus on, 383 (Jul)
Glucophage, update on, 249 (May)
methotrexate
Crohn's disease, for Tx of (abstr), 410 (Jul)
metronidazole
Flagyl, update on, 368 (Jul)
metronidazole topical cream
MetroCream, update on, 639 (Nov)
milrinone lactate
Primacor, update on, 12 (Jan)
misoprostol
elderly patients with rheumatoid arthritis, for prevention of GI problems in, 561 (Oct)
moexipril HCl
Univasc, update on, 428 (Aug)
multiple sclerosis
recombinant interferon beta-1A for Tx of, 655 (Nov)
mupirocin nasal ointment
Bactroban, update on, 636 (Nov)
murine monoclonal infectious disease imaging agent
osteomyelitis, for diagnosing, 722 (Nov)
mycophenolate mofetil capsules
CellCept, update on, 490 (Sept)
myocardial infarction
anticoagulation after (abstr), 410 (Jul)
management of, 79 (Feb)
new t-PA compared with other Tx modalities for, 258 (May)
preventing second, 651 (Nov)
thrombolytics vs pharmacologic therapy after, 80

(Feb)
t-PA, double bolus, for Tx of, 568 (Oct)
underuse of beta blockers after, 370 (Jul)
warfarin, cost-effectiveness of use after, 310 (Jun)

N

nalmefene HCl injection
Revex, update on, 368 (Jul)
naltrexone HCl
ReVia, update on, 193 (Apr)
naproxen, delayed-release
EC-Naprosyn, update on, 11 (Jan)
nefazodone HCl
focus on, 205 (Apr)
Serzone, update on, 132 (Mar)
niacin
lovastatin, vs, for Tx of hypercholestrolemia, 21 (Jan)
nimodipine
elderly, facilitates learning of, 134 (Mar)
nitrate-free interval
definition of (letter), 51 (Jan)
nitroglycerin patches
Minitran, update on, 69 (Feb)
nizatidine
Axid, update on, 189 (Apr)
norfloxacin
Noroxin, update on, 492 (Sept)
NSAIDs
acute low back pain, for Tx of, 70 (Feb)

O

omeprazole
clarithromycin, and, for Tx of *H pylori*-associated duodenal ulcers, 431 (Aug)
cost effective for GERD, 760 (Dec)
GERD, for Tx of, 216 (Apr)
omeprazole delayed-release capsules
Prilosec, update on, 250 (May); 492 (Sept)
ondansetron
granisetron, vs, as financially attractive agent, 72 (Feb)
Zofran Tablets, update on, 305 (Jun)
osteomyelitis
new imaging agent for diagnosing, 722 (Nov)
osteoporosis
alendronate sodium for Tx of, 433 (Aug)
otitis media, acute
amoxicillin/clavulanate potassium for Tx of, 721 (Nov)
outcome measurements
improving, 501 (Sept)
outcomes research
data from, wanted by pharmacists, 506 (Sept)
Who should conduct? (FormuFax), 171 (Mar)
oxazolidinones
gram-positive organisms, a new class of drugs effective against, 722 (Nov)

P

package inserts
FDA proposes mandatory patient information in, 622 (Oct)
paclitaxel
ovarian cancer, for Tx of, 434 (Aug)
Taxol, update on, 132 (Mar)
pain management
computers used in, 70 (Feb)
tramadol for use in, 321 (Jun)
pamidronate disodium for injection
Aredia, update on, 188 (Apr)
pancrelipase, microspheric delivery system
Ultrase, update on, 755 (Dec)
Parkinson's disease
medication compliance, and, 14 (Jan)
pegaspargase
asparaginase, vs, for Tx of acute lymphocytic leukemia in adults, 388 (Jul)
penicillin
bid better than qid, in Tx of streptococcal pharyngitis (abstr), 292 (May)
peptic ulcers
empiric therapy is cost effective (abstr), 822 (Dec)
H pylori infections and, 28 (Jan)
pharmaceutical claims
using data from, for case management, 501 (Sept)
pharmaceutical companies
incentive programs, and (FormuFax), 54 (Jan)
mergers of, and effects on budgets, 200 (Apr)
product liability claims and, 238 (Apr)
relationship with healthcare professionals, and, 161 (Mar)
pharmacist intervention program
goals of, 433 (Aug)
pharmacist-prescribed drug class
pros and cons of, 653 (Nov)
pharmacists
liability for substitutions, and (FormuFax), 290 (May)
reimbursement for services of, 315 (Jun)
pharmacoeconomics
depression, the treatment of, issues in (Suppl), S-20 (Sept)
formulary decision making, and, 42 (Jan)
issues affecting, 20 (Jan)
studies of, standards for, 373 (Jul); 561 (Oct)
Pharmacy & Therapeutics Committee
adapting, in managed care, 138 (Mar)
pharmacy benefit management companies
challenges and cost savings associated with, 12 (Jan)
physicians
report cards for (FormuFax), 619 (Oct)
pipeline
agents in the, 10 (Jan); 68, 72 (Feb); 128 (Mar); 188 (Apr); 248 (May); 304 (Jun); 367 (Jul); 422 (Aug); 488 (Sept); 556 (Oct); 636 (Nov); 740 (Dec)
piperacillin/tazobactam
ceftazidime, vs, for Tx of hospital-acquired lower respiratory tract infections, 563 (Oct)
ticarcillin/clavulanate, vs, for Tx of lower respiratory tract infections, 719 (Nov)
pneumonia
community-acquired:
early switch to oral antibiotics in Tx of (abstr), 723 (Nov)
using azithromycin as adjuvant therapy in Tx of 817, (Dec)
pneumocystic:
chemoprophylactic regimens for, 28 (Jan)
prophylaxis against (abstr), 544 (Sept)
practice guidelines
Minnesota MCO reports success creating, 762 (Dec)
pravastatin sodium
carotid artery atherosclerosis, for Tx of, 79 (Feb)
prednisolone
rheumatoid arthritis, as adjunctive therapy for (abstr), 723 (Nov)
prenatal multivitamin/mineral supplement
Zenate, Advanced Formula, update on, 70 (Feb)
prescribing practices
disease-based-outcome approach to, with antibiotics, 139 (Mar)
documenting, 378 (Jul)
how to change, 138 (Mar)
propofol
Diprivan Injection, update on, 10 (Jan)
psychiatric disorders
drugs for Tx of, in pipeline, 72 (Feb)

Q

quality of care
AHCPR publishes guidelines for, 567 (Oct)

R

ramipril capsules
Altace, update on, 367 (Jul); 636 (Nov)
ranitidine
Zantac, update on, 369 (Jul)
Rh$_o$(D) immune globulin IV, human
WinRho SD, update on, 369 (Jul)
riluzole
Rilutek, update on, 492 (Sept)
rimexolone ophthalmic suspension
Vexol 1%, update on, 197 (Apr)

S

salmeterol xinafoate
Serevent Inhalation Aerosol, update on, 132 (Mar)
saquinavir
shows resistance much slower than other proteinase inhibitors, 759 (Dec)
sargramostim
Leukine/Immunex, update on, 639 (Nov)
schizophrenia
oral vs depot administration in Tx of, 15 (Jan)
scientific information
FDA regulation of exchange of (FormuFax), 619 (Oct)
seizure disorders, refractory
vigabatrin for Tx of, 143 (Mar)
seizures
incidence of, associated with imipenem use, 172 (Mar)
selegiline
Eldepryl, update on, 128 (Mar); 368 (Jul)
sertraline HCl
Zoloft, update on, 495 (Sept)
sevoflurane volatile liquid for inhalation
Ultane, update on, 492 (Sept)
simvastatin
cholesterol lowering, for, in patients with CHD, 254 (May)
Zocor, update on, 495 (Sept)
sodium chloride/sodium bicarbonate/potassium chloride GI lavage bowel prep
NuLytely, Cherry Flavor, update on, 131 (Mar)
somatropin
Norditropin, update on, 427 (Aug)
statin therapy
CAD, for lowering cholesterol in patients with, 253 (May)
streptococcal pharyngitis
bid penicillin better than qid for Tx of (abstr), 292 (May)
stroke
warfarin underused for, 758 (Dec)
sumatriptan succinate
Imitrex, update on, 69 (Feb); 427 (Aug)

T

tacrine HCl
Cognex, update on, 422 (Aug)
technetium Tc99m bicisate injection
Neurolite, update on, 193 (Apr)
technetium Tc99m exametazime injection
Ceretec, update on, 367 (Jul)
technetium (Tc)-99m sestamibi
chest pain, for assessment of, 74 (Feb)
terazosin
finasteride, vs, for Tx of BPH, 650 (Nov)

testosterone transdermal system
Androderm, update on, 740 (Dec)
tetracycline HCl-impregnated peridontal fiber
Actisite, update on, 488 (Sept)
thalidomide
Andrulis, update on, 557 (Oct)
Synovir, update on, 557 (Oct)
theophylline
Uni-Dur Extended-Release Tablets, update on, 197 (Apr)
therapeutic interchange
antibiotics, of, 92 (Feb)
evaluation method for, 137 (Mar)
thiotepa
Thioplex, update on, 369 (Jul)
thromboembolism, venous
extending anticoagulation for Tx of (abstr), 621 (Oct)
thrombolytics
pharmacologic therapy, vs, after myocardial infarction, 80 (Feb)
risks vs benefits of, 257 (May)
tiagabine HCl
intractable epilepsy, for Tx of, 133 (Mar)
ticarcillin/clavulanate
piperacillin/tazobactam, vs, for Tx of lower respiratory tract infections, 719 (Nov)
tissue plasminogen activator (t-PA)
double bolus, for Tx of myocardial infarction, 568 (Oct)
ischemic stroke, for Tx of, 198 (Apr)
new, compared with other therapies for Tx of acute MI, 258 (May)
tramadol HCl
alternative dosing for (letter), 542 (Sept)
focus on, 321 (Jun)
Ultram, update on, 250 (May)
trimethoprim HCl
Primsol, update on, 640 (Nov)
trimetrexate glucuronate
dosing guidelines for, 349 (Jun)
typhoid Vi polysaccharide vaccine
Typhim Vi, update on, 197 (Apr)

U

urethritis, nongonococcal
single-dose azithromycin cures most men with (abstr), 821 (Dec)
urinary tract infections
uncomplicated, three-day ciprofloxacin for Tx of (abstr), 474 (Aug)
uterine leiomyoma
gonadotropin-releasing hormone, use of, before surgery for, 532 (Sept)

V

valacyclovir HCl
Valtrex, update on, 640 (Nov)
vancomycin
CDC recommends restricting use of, to slow spread of vancomycin-resistant organisms, 756 (Dec)
serum concentrations, need to monitor, 28 (Jan)
varicella virus vaccine live
Varivax, update on, 428 (Aug)
venlafaxine HCl
Effexor, update on, 128 (Mar)
vigabatrin
focus on, 143 (Mar)
vinorelbine tartrate
Navelbine, update on, 130 (Mar)

W

warfarin sodium
cardiovascular disease, for Tx of, focus on, 657 (Nov)
cost-effective use of, post-MI, 310 (Jun)
Coumadin, update on, 422 (Aug); 556 (Oct)
underused in stroke, 758 (Dec)

Z

zidovudine/zalcitabine/saquinavir
extended use of, for improved HIV suppression, 720 (Nov)

A

Agrawal, N.M.; van Kerckhove, H.E.J.; Erhardt, L.J., et al: Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers: A one-year study (abstr), 830 (Dec)
Ahkee, S.: See Ramirez, J.A.
Albertson, Timothy E.: See Romac, Diane R.
Anassi, Enock O.; Ericsson, Charles; Lal, Lincy; McCants, Ellecya: Using a pharmaceutical restriction program to control antibiotic use, 711 (Nov)
Andreski, Mike: Shortened FDA drug approval process (FormuFax), 290 (May)
Arriola, Ed: The changing relationship between health care professionals and the pharmaceutical industry, 161 (Mar)
Attman, Robert L.: Report cards for physicians (FormuFax), 620 (Oct)

B

Bakst, Alan: Pharmacoeconomics and the formulary decision-making process, 42 (Jan)
Baldinger, Sandra L.; Chow, Moses S.S.; edited by Chow, Moses S.S.: Focus on anticoagulants: Warfarin's new indication for cardiovascular disaese and enoxaparin's new indication for knee replacement surgery, 657 (Nov)
Barclay, Linh P.; Hatton, Randy C.; Doering, Paul L.; Shands, Joseph W.: Physicians' perceptions and knowledge of drug costs: Results of a survey, 268 (May)
Barkin, Robert L.: Alternative dosing for tramadol aids effectiveness (letter), 542 (Sept)
Barkin, Robert L.; edited by Chow, Moses S.S.: Focus on tramadol: A centrally acting analgesic for moderate to moderatly severe pain, 321 (Jun)
Bedossa P.: See Poynard T.
Ben-Joseph, Rami; Segal, Richard; Russell, Wayne L.; Oh, Taeho: Evaluating the value, accuracy, and operational feasibility of DUE criteria, 280 (May)
Berardi, Rosemary R.; Dunn-Kucharski, Valerie A.: Omeprazole: Defining its role in gastroesophageal reflux disease, 216 (Apr)
Berelowitz, M.; Fischette, C.; Cefalu, W.; et al: Newer, controlled-release glipizide is superior to older treatment (abstr), 236 (Apr)
Bilianou, H.I.: See Kolovou, G.D.
Boston, David; Collins, Christine: Safety, efficacy, and lipid profile of doxazosin at a VA medical center, 233 (Apr)
Brandot, Milan E.: Shortened FDA approval process (FormuFax), 409 (Jul)
Breedveld, F.C.: Combination therapy for rheumatoid arthritis may be here to stay (abstr), 723 (Nov)
Breiman, R.F.; Butler, J.C.; Tenover, F.C.; et al: Pneumococcal strains show increasing resistance to drugs (abstr), 56 (Jan)
Brier, Kenneth Leo: Pharmaceutical management strategies of industrialized countries, 606 (Oct)
Briglia, R.: Who should conduct outcomes research? (FormuFax), 171 (Mar)
Brown, Jean: Report cards for physicians (FormuFax), 620 (Oct)
Brown, Russell: Do managed care formularies ignore the individual patient? (FormuFax), 815 (Dec)
Bryant, Bobby: See Lomaestro, Ben M.
Bryzinski, B.S.: See Frishman, W.H.
Butler, J.C.: See Breiman, R.F.

C

Cairns, J.A.; Markham, B.A.: Benefits of long-term post-MI anticoagulation outweigh the costs (abstr), 410 (Jul)
Calmes, Helen M.: Shortened FDA approval process (FormuFax), 409 (Jul)
Campbell, Margaret M.; edited by Chow, Moses S.S.: Focus on vigabatrin: A second-generation antiepileptic agent for treatment of refractory seizure disorders, 143 (Mar)
Cefalu, W.: See Berelowitz, M.
Chase, Kathy: See Wooten, James M.
Chernew, M.E.: See Fendrick, A.M.
Cheung, Andrew: See O'Donovan, Carmel A.
Chevallier M.: See Poynard T.
Chow, Moses S.S.:
See Baldinger, Sandra L.
See Barkin, Robert L.
See: Campbell, Margaret M.
See: Dopheide, Julie A.
See: King, Jeffrey H.
See: Matthews, S. James
See: Patel, Kalpana B.
See: Tran, Hieu T.
See Sharma, Roopali
See: Udeh, Elizabeth
See: Wachsman, Matt
Chutka, Darryl S.: Selection of antihypertensive medications for the elderly, 148 (Mar)
Cimato, Dominic A.: Do managed care formularies ignore the individual patient? (FormuFax), 815 (Dec)
Cohen, Lawrence J.: Pharmacoeconomic issues in the treatment of depression (Suppl), S-20 (Sept)
Cohen, Michael R.: Mandatory medication error reporting (FormuFax), 53 (Jan)
Cohen, Stuart H.: See King, Jeffrey H.
Collins, Christine: See Boston, David
Colodner, R.: See Raz, R.
Coulson, L.R.: See Frishman, W.H.
Couto, A.J.: Manufacturers' compensation programs (FormuFax), 55 (Jan)
Crane, Vicki S.: See Gonzalez, Edgar R.

D

Dahlgren, Thomas E.: Should FDA continue to regulate the exchange of scientific information? (FormuFax), 619 (Oct)
de Vries, R.J.M.; Dunselman, P.H.J.: van Veldhuisen, D.J.; et al: Felodipine reduces ischemia in older patients already on beta blockade (abstr),

176 (Mar)
Diaz, Margarita Velazquez: Generic substitutions (FormuFax), 291 (May)
DiMatteo, M. Robin: Patient adherence to pharmacotherapy: The importance of effective communication, 596 (Oct)
Doering, Edmund III: Cooperation among MCOs (FormuFax), 620 (Oct)
Doering, Paul L.: See Barclay, Linh P.
Dopheide, Julie A.; Stimmel, Glen L.; Yi, Donna D.; edited by Chow, Moses S.S.: Focus on nefazodone: A serotonergic drug for major depression, 205 (Apr)
Douglas, M.B.: See Hawkins, D.W.
Downing, Arlene: Manufacturers' compensation programs (FormuFax), 54 (Jan)
Dreiman, Randall: Role of pharmaceutical industry in disease management programs (FormuFax), 409 (Jul)
Dujovne, C.A.: See Schrott, H.G.
Dunn-Kucharski, Valerie A.: See Berardi, Rosemary R.
Dunselman, P.H.J.: See de Vries, R.J.M.

E

Elchanan, G.: See Raz, R.
Ereshefsky, Larry: Antidepressants: A pharmacologic rationale for treatment and product selection (Suppl), S-10 (Sept)
Erhardt L.J.: See Agrawal N.M.
Ericsson, Charles: See Anassi, Enock O.
Erickson, Jan: Who should conduct outcomes research? (FormuFax), 171 (Mar)

F

Fan-Havard, Patty: See O'Donovan, Carmel A.
Feagan, B.G.; Rochon, J.; Fedorak, R.N.; et al: Crohn's disease: Methotrexate can reduce prednisone requirements (abstr), 410 (Jul)
Fedorak, R.N.: See Feagan, B.G.
Fendrick, A.M.; Chernew, M.E.; Hirth, R.A.; et al: Alternative management strategies for patients with suspected peptic ulcer disease (abstr), 822 (Dec)
Fennerty, M. Brian; Melnyk, Clifford S.: *Helicobacter pylori*: Review of triple, dual, 7-day, and other treatment strategies, 682 (Nov)
Fiorello, Steven J.: Developing and implementing a statewide formulary system: One state's experience, 808 (Dec)
Fischette, C.: See Berelowitz, M.
Fostinis, Y.P.: See Kolovou, G.D.
Foulke, Garrett: See Romac, Diane R.
Frighetto, Luciana; Nickoloff, Donna; Jewesson, Peter: Antibiotic therapeutic interchange program: Six years of experience, 92 (Feb)
Frishman, W.H.; Bryzinski, B.S.; Coulson, L.R.; et al: Consider beta blocker plus diuretic as first-line therapy for hypertension (abstr), 56 (Jan)
Funk, Paula A.: See Orsini, Michael J.

G

Gaddis, Gary M.: Let marketplace dictate reform, not government (FormuFax), 172 (Mar)
Gallant, J.E.; McAvinue, S.M.; Moore, R.D.; et al: *Pneumocystis carinii* pneumonia prophylaxis reduces mortality, costs (abstr), 544 (Sept)
Gallina, Joseph N.: See Orsini, Michael J.
Garg, R.: Yusus, S.: Support is substantial for routinely prescribing ACE inhibitors for CHF (abstr), 474 (Aug)
Gatty, Bob:
Drive to reform the FDA gains momentum, 178 (Mar)
FDA says `Look at the facts' when judging its record on drug approvals, 412 (Jul)
Health issues on hold, but lurking behind GOP's Contract with America, 118 (Feb)
Industry successfully killing proposals to ban discounts on pharmaceuticals, 354 (Jun)
Medicaid, FDA reform key issues building steam in Congress, 294 (May)
Medicaid, Medicare reform proposals stir debate over prescription benefits, 546 (Sept)
Pharmaceutical industry wins "round one" in protections against product liability claims, 238 (Apr)
Who would approve new drugs if there were no FDA? 58 (Jan)
Will politics sidetrack FDA reform? 476 (Aug)
Geckler, R.W.: See Nichols, R.L.
Gheorghiade, M.: See Ward, R.E.
Göbel, E.J.A.: See Portegies, M.C.M.
Goeckner, Byron J.: See Peters, Byron G.
Goldstein, Elliot: See Klutman, Neil E.
Gonzalez, Edgar R.; Crane, Vicki S.: Designing a disease management program: How to get started, 326 (Jun)

H

Hain, R.: Manufacturers' compensation programs (FormuFax), 55 (Jan)
Hall, W.D.: See Hawkins, D.W.
Hatton, Randy C.: See Barclay, Linh P.
Havlichek, Daniel: See Stein, Gary E.
Hawkins, D.W.; Hall, W.D.; Douglas, M.B.; et al: Two ACE inhibitors shown effective for treating hypertension in elderly (abstr), 292 (May)
Hennessey, Collin: See Stein, Gary E.
Henry, R. Beth: See Wooten, James M.
Hicks, C.B.: See Stamm, W.E.
Hillner, B.E.: See Smith, T.J.
Hinrichs, Thomas F.: Are formularies on "the endangered species" list? (FormuFax), 816 (Dec)
Hirth, R.A.: See Fendrick, A.M.
Hitt, Catherine M.: See Patel, Kalpana B.
Howard, Lyn: See Malone, Margaret
Hughes, J.M.: See McCraig, L.F.
Hunter, Dee A.: See Hunter, Walter
Hunter, Walter; Hunter, Dee A.:
Defining the nitrate-free interval (letter), 51 (Jan)
Mandatory medication error reporting (FormuFax), 54 (Jan)

I

Iacovelli, Lewis M.: Report cards for physicians (FormuFax), 620 (Oct)
Iravani, A.; Tice, A.D.; McCarty, J.; et al: Three days of therapy with ciprofloxacin effective for uncomplicated UTI (abstr), 474 (Aug)

J

Jewesson, Peter: See Frighetto, Luciana
Johnson, Elizabeth: See Saltiel, Emmanuel
Johnson, Jon D.: Do managed care formularies ignore the individual patient? (FormuFax), 815 (Dec)
Jonker, J.J.C.: See van Bergen, P.F.M.

K

Kamp, S.: Are formularies on "the endangered species" list? (FormuFax), 816 (Dec)
Kaufman, Rich: Shortened FDA drug approval process (FormuFax), 290 (May)
King, Jeffrey H.; Cohen, Stuart H.; edited by Chow, Moses S.S.: Focus on ceftibuten: A third-generation oral cephalosporin antibiotic, 85 (Feb)
Kirwan, J.R.: Combination therapy for rheumatoid arthritis may be here to stay (abstr), 723 (Nov)
Klaassen, Spencer: Should FDA continue to regulate the exchange of scientific information? (FormuFax), 619 (Oct)
Klepser, Michael E.: See Patel, Kalpana B.
Kluger, Jeffrey: See Tran, Hieu T.
Klutman, Neil E.; Goldstein, Elliot: Changing recommendations in infectious disease: *H pylori* infection, vancomycin monitoring, and *P carinii* prophylaxis, 28 (Oct)
Koff, R.S.: See Wong, J.B.
Kolovou, G.D.; Fostinis, Y.P.; Bilianou, H.I.: Baseline HDL levels may predict response to lipid-lowering therapy (abstr), 291 (May)
Korelitz, Burton I.: See Rubin, Steven D.
Kramer, Marty: See Sharma, R.
Kraynak, Maura A.: See Reis, Andrea J.

L

Lal, Lincy: See Anassi, Enock O.
LaPorta Mark A.: Role of pharmaceutical industry in disease management programs (FormuFax), 409 (Jul)
Larrat, E. Paul: Defining the nitrate-free interval (reply to letter), 52 (Jan)
Lauring, Richard: Pharmacists' share in decision-making risk (FormuFax), 290 (May)
Lesar, Timothy S.: See Lomaestro, Ben M.
Levine, W.C.: See Moran, J.S.
Lindmarker, P.: See Schulman, S.
Lomaestro, Ben M.; Lesar, Timothy S.; Snow, Karla S.; Bryant, Bobby: Ceftriaxone DUE in a pediatric population, 615 (Oct)

M

Mackowiak, Leslie: See Vrabel, Rayburn B.
Madura, Albert J.: See Tse, Ted
Mahackian, Kathleen: See Romac, Diane R.
Malone, Margaret; Howard, Lyn: Evaluating an enteral nutrition support service, 714 (Nov)
Marangos, Markos N: Patel, Kalpana B.
Markham, B.A.: See Cairns, J.A.
Martin, D.H.: See Stamm, W.E.
Maswoswe, Jordan J.: See Okpara, Alphonsus U.
Matthews, S. James; edited by Chow, Moses S.S.: Focus on metformin: A new biguanide antihyperglycemic agent, 383 (Jul)
Matuschka, Paul; Vissing, Rick: Glipizide to glyburide conversion in patients with type II diabetes mellitus, 405 (Jul)
Mazzel, C.S.: Shortened FDA drug approval process (FormuFax), 290 (May)
McAvinue, S.M.: See Gallant, J.E.
McCall, Charles Y.: See Wade, William E.
McCants, Ellecya: See Anassi, Enock O.
McCarty, J.: See Iravani, A.
McCraig, L.F.; Hughes, J.M.: Prescribing trend: Physicians using newer antibiotics (abst), 292 (May)
Meltzer, Barton A.: Are formularies on "the endangered species" list? (FormuFax), 816 (Dec)
Melnikow, J: See Nuovo J.
Melnyk, Clifford S.: See Fennerty, M. Brian
Mitchell, John: Manufacturers' compensation programs (FormuFax), 55 (Jan)
Moore, R.D.: See Gallant, J.E.
Moseley, Carole: See Anassi, Enock O.
Mutnick, Alan H.: See Peroutka, Julie A.

N

Neighbors, D.M.: See Smith, T.J.
Newman, Mary Beth: Mandatory medication error reporting (FormuFax), 54 (Jan)

Nichols, R.L.; Smith, J.W.; Geckler, R.W.: Investigational carbapenem antibiotic offers dosing advantages (abstr), 724 (Nov)
Nickoloff, Donna: See Frighetto, Luciana
Nicolau, David P.: See Patel, Kalpana B.
Nightingale, Charles H.: See Patel, Kalpana B.
Nightingale, R.H.: Are formularies on "the endangered species" list? (FormuFax), 816 (Dec)
Nuovo J.; Melnikow, J; Paliescheskey, M; et al: Doxycycline shown most cost-effective for *C trachomatis* cervicitis (abstr), 291 (May)

O

O'Connor, Mary C.: See Wooten, James M.
O'Donovan, Carmel A.; White, Monica L.; Cheung, Andrew; Fan-Havard, Patty: Seizure incidence with imipenem use at a VA hospital, 172 (Mar)
Oh, Taeho: See Ben-Joseph, Rami
Okpara, Alphonsus U.; Maswoswe, Jordan J.; Stewart, Kenneth: Criteria-based antimicrobial IV to oral conversion program, 343 (Jun)
Orsini, Michael J.; Funk, Paula A.; Thorn, Deborah B.; Gallina, Joseph N.: An ADR surveillance program: Increasing quality, number of incidence reports, 454 (Aug)
Owings, John T.: See Romac, Diane R.

P

Paliescheskey M: See Melnikow, Nuovo J.
Patel, Kalpana B.; Nicolau, David P.; Klepser, Michael E.; Marangos, Markos N; Hitt, Catherine M.; Nightingale, Charles H.; edited by Chow, Moses S.S.: Focus on fleroxacin: A new once-daily fluoroquinolone antibiotic, 261 (May)
Pearson, Noel: Should FDA continue to regulate the exchange of scientific information? (FormuFax), 619 (Oct)
Peroutka, Julie A.; Mutnick, Alan H.: Use of decision analysis to evaluate the costs and benefits of filgrastim (G-CSF) therapy, 394 (Jul)
Peters, Byron G.; Goeckner, Byron J.; Ponzillo, John J.; Velasquez, William S.; Wilson, Andrew L.: Pegaspargase versus asparaginase in adult ALL: A pharmacoeconomic assessment, 388 (Jul)
Pincus, T.: See Tugwell, P.
Ponzillo, John J.: See Peters, Byron G.
Poole, Patricia: See Romac, Diane R.
Portegies, M.C.M.; Sijbring, P; Göbel, E.J.A.; et al: Use beta blockers for silent ischemia in patients with stable angina (abstr), 176 (Mar)
Potts, Truman A.: Legislation on equal access to discounts (FormuFax), 55 (Jan)
Poynard T.; Bedossa P.; Chevallier M.; et al: Use high-dose, long-term interferon for chronic non-A, non-B hepatitis (abstr), 544 (Sept)

R

Ramirez, J.A.; Srinath, L.; Ahkee, S.; et al: Community-acquired pneumonia: Early switch to oral antibiotics can cut costs (abstr), 723 (Nov)
Raz, R.; Elchanan, G.; Colodner, R.; et al: Twice-daily penicillin superior to QID regimen for streptococcal phraryngitis (abstr), 292 (May)
Reis, Andrea J.; Kraynak, Maura A.: Adapting a commercially available software program to improve ADR reporting, 697 (Nov)
Rhedin, A.-S.: See Schulman, S.
Rochon, J.: See Feagan, B.G.
Roe, Whitney: Manufacturers' compensation programs (FormuFax), 55 (Jan)
Romac, Diane R.; Poole, Patricia; Owings, John T.; Mahackian, Kathleen; Foulke, Garrett; Tharratt, Steven; Albertson, Timothy E.: Developing guidelines for biotechnology drug use: Experience with antithrombin III, 520 (Sept)
Ross, Mary B.: See Szymusiak-Mutnick, Barbara A.
Rubin, Steven D.; Korelitz, Burton I.: Immunomodulator therapy in severe inflammatory bowel disease, 784 (Dec)
Russell, Wayne L.: See Ben-Joseph, Rami

S

Saltiel, Emmanuel: Potential cost savings using GnRH agonists as preoperative therapy for uterine leiomyomas, 532 (Sept)
Saltiel, Emmanuel; Johnson, Elizabeth; Shane, Rita: A team approach to adverse drug reaction surveillance: Success at a tertiary care hospital, 226 (Apr)
Schnabel, Joe: Manufacturers' compensation programs (FormuFax), 54 (Jan)
Schraffenberger, Don W.: Generic substitutions (FormuFax), 291 (May)
Schrott, H.G.; Stein, E.A.: Dujovne, C.A.; et al: Combination therapy with low-dose colestipol and lovastatin lowers LDL (abstr), 236 (Apr)
Schulman, S.; Rhedin, A.-S.; Lindmarker, P.; et al: Extending anticoagulant regimen helps prevent thromboembolisms (abstr), 621 (Oct)
Segal, Richard: See Ben-Joseph, Rami
Shands, Joseph W.: See Barclay, Linh P.
Shane, Rita: See Saltiel, Emmanuel
Sharma, Roopali; Kramer, Marty; edited by Chow, Moses S.S.: Focus on dirithromycin: A new once-daily macrolide antibiotic, 769 (Dec)
Sijbring, P: See Portegies, M.C.M.
Smith, J.W.: See Nichols, R.L.
Smith, T.J.; Hillner, B.E.; Neighbors, D.M.; et al: Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer (abstr), 822 (Dec)
Snow, Karla S.: See Lomaestro, Ben M.
Srinath, L.: See Ramirez, J.A.
Stamm, W.E.; Hicks, C.B.; Martin, D.H.; et al: Azithromycin for empirical treatment of the nongonoccal urethritis syndrome in men (abstr), 821 (Dec)
Stein, E.A.: See Schrott, H.G.
Stein, Gary E; Havlichek, D; Hennessey, Collin: Using azithromycin as adjuvant, empiric therapy to treat community-acquired pneumonia, 817 (Dec)
Stewart, Ken: See Anassi, Enock O.
Stewart, Kenneth: See Okpara, Alphonsus U.
Stimmel, Glen L.: See Dopheide, Julie A.
Stoogenke, Marvin M.: Who should conduct outcomes research? (FormuFax), 172 (Mar)
Szymusiak-Mutnick, Barbara A.; Ross, Mary B.: Increased adverse drug reaction reporting through wall-mounted ADR reporting cards, 471 (Aug)

T

Taniguichi, George: Do managed care formularies ignore the individual patient? (FormuFax), 815 (Dec)
Tenover, F.C.: See Breiman, R.F.
Tetenman, Stanley L.: Discriminatory pricing policies are discriminatory (letter), 543 (Sept)
Tharratt, Steven: See Romac, Diane R.
Thorn, Deborah B.: See Orsini, Michael J.
Tice, A.D.: See Iravani, A.
Tinè, F.: See Wong, J.B.
Tran, Hieu T.; Kluger, Jeffrey; Chow, Moses S.S.; edited by Chow, Moses S.S.:
Focus on dofetilide: A selective class III antiarrhythmic agent, 23 (Jan)
Focus on IV amiodarone: A new formulation for acute arrhythmia treatment, 509 (Sept)
Tse, Ted; Madura, Albert J.: Initiating a drug blood level monitoring program through CQI, 284 (May)
Tugwell, P.; Pincus, T.; Yocum, D.; et al: Combination therapy for rheumatoid arthritis may be here to stay (abstr), 723 (Nov)

U

Udeh, Elizabeth; Zaldonis, Anthony T.; edited by Chow, Moses S.S.: Focus on lansoprazole: A new proton pump inhibitor for gastric acid-related disorders, 437 (Aug)

V

van Bergen, P.F.M.; Jonker, J.J.C.; van Hout, B.A.; et al: Benefits of long-term post-MI anticoagulation outweigh the costs (abstr), 410 (Jul)
van Hout, B.A.: See van Bergen, P.F.M.
van Kerckhove H.E.J.: See Agrawal N.M.
van Veldhuisen, D.J.: See de Vries, R.J.M.
Velasquez, William S.: See Peters, Byron G.
Vissing, Rick: See Matuschka, Paul
Vrabel, Rayburn B.; Mackowiak, Leslie: Automation in pharmacy: Two institutions' experiences with novel distribution systems, 106 (Feb)

W

Wachsman, Matt; edited by Chow, Moses S.S.: Focus on famciclovier: Review of its use in genital herpes simplex virus therapy, 587 (Oct)
Wade, William E.; McCall, Charles Y.: How a CQI program improved aminoglycoside use in a community hospital, 114 (Feb)
Ward, R.E.; Gheorghiade, M.; Young J.B.; et al: Continuing digoxin therapy in patients wtih stable CHF is cost-effective (abstr), 621 (Oct)
Wedworth, Emily Burton: Legislation on equal access to discounts (FormuFax), 55 (Jan)
Wechsler, Jill:
FDA considers effects of managed care marketplace on drug promotional practices, 840 (Dec)
FDA puts forth proposal to mandate patient information, 622 (Oct)
Increased contributions, decreased fees, managed care are key Medicare reform issues, 730 (Nov)
Wells, Barbara G.: Issues in diagnosis of major depressior. (Suppl), S-3 (Sept)
White, Monica L.: See O'Donovan, Carmel A.
Wilson, Andrew L.: See Peters, Byron G.
Wilson, Ellis, Jr.: Do managed care formularies ignore the individual patient? (FormuFax), 815 (Dec)
Witkowski, Paul: Should FDA continue to regulate the exchange of scientific information? (FormuFax), 619 (Oct)
Wong, J.B.; Koff, R.S.; Tinè, F.; et al: Interferon shows clinical and economic advantages in hepatitis B therapy (abstr), 724 (Nov)
Wong, T.: Are formularies on "the endangered species" list? (FormuFax), 816 (Dec)
Wooten, James M.; Chase, Kathy; O'Connor, Mary C.; Henry, R. Beth: Dosing guidelines for foscarnet and trimetrexate, 349 (Jun)

Y

Yi, Donna D.: See Dopheide, Julie A.
Yocum, D.: See Tugwell, P.
Young J.B.: See Ward, R.E.
Yusus, S.; See Garg, R.

Z

Zaldonis, Anthony T.: See: Udeh, Elizabeth